Social Cognition in Huntington's Disease: Cognitive Study and Functional and Morphological Imaging (COSIMH)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49000
- CHU Angers
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For all particpipants
- Patient gave its written consent
- between 20 and 70 years
- School level : at least 7 years
- native language: french
For presymptomatic patient
- Huntington's disease diagnosed with abnormal number of CAG repeats: 36 < nucleotide expansion (CAG)
- Unified Huntington Disease Rating Scale moteur ≤ 5
For symptomatic patient
- Huntington's disease diagnosed with abnormal number of CAG repeats: 36 < nucleotide expansion (CAG)
- Unified Huntington Disease Rating Scale moteur > 5
Exclusion Criteria:
- No national health insurance affiliation
- Being under guardianship
- Meeting brain MRI exclusion criteria (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin, or body, Renal failure, hypersensitivity of Gadolinium) or refusing MRI
- Pregnant or lactating women
- Patient with involuntary movement hampering the realization of MRI
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: presymptomatic patient
patient with Unified Huntington's Disease Rating Scale (UHDRS) < 5
|
|
|
Other: symptomatic patient
patient with Unified Huntington's Disease Rating Scale (UHDRS) > 5
|
|
|
Other: controls
unaffected patient with Huntington's disease
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the achievement of social cognition process in Huntington's disease using the total score of the scale 15-TOM
Time Frame: 3 months after inclusion
|
3 months after inclusion
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: SCHERER GAGOU, University Hospital, Angers
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Dyskinesias
- Heredodegenerative Disorders, Nervous System
- Dementia
- Cognition Disorders
- Chorea
- Huntington Disease
Other Study ID Numbers
Other Study ID Numbers
- AOI 201409
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.